21st Annual HCNE Boston Fall Headache Symposium Headache ...
Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical...
Transcript of Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical...
![Page 1: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/1.jpg)
Headache – A Practical Approach
Integrated Pain SymposiumDecember 1, 2017
Alyssa Lettich. MDNeurosciences Institute/Neurosciences Clinical ProgramMedical Director Headache and Pain Development Teams
![Page 2: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/2.jpg)
Disclosures: none
![Page 3: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/3.jpg)
Learning Outcomes
At the conclusion of this activity, you should be able to
1) Assess for and identify headache red flags/worrisome symptoms
2) Discuss medication overuse/MOH headache
3) Correctly diagnose common headache disorders and initiate treatment
4) Review general principles of headache management for migraine and tension-type headache
![Page 4: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/4.jpg)
Neurosciences Pain Development Team
A coordination of efforts to reduce opioid misuse across neurosciences including for the treatment of headache, neck pain, LBP, and neuropathy
Goals for 2018 include a 40% decrease in opioid prescriptions
• Acute cluster headache treatment guideline
• Injectable and non-injectable acute migraine treatment guideline
• Painful peripheral neuropathy flashcard
• LBP flashcard update
• Neck pain and LBP CPM update to reflect opioid reduction goals and PAMA imaging support
![Page 5: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/5.jpg)
What is a headache?
Headache is defined as pain in the head that is located above the eyes or the ears, behind the head (occipital), or in the back of the upper neck.
![Page 6: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/6.jpg)
Headaches
Secondary headaches – a headache due to some underlying cause
• Medication overuse/medication overuse headache
Primary headaches
• Migraine*
• Tension-type headache*
• Cluster headache and other trigeminal autonomic cephalalgias
• Other primary headaches
![Page 7: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/7.jpg)
Red Flags
Systemic symptoms (fever, weight loss) or Secondary risk factors (HIV, cancer)Neurologic symptoms or Neurologic signs including level of arousalOnset: sudden, abrupt, or split-secondOlder: new-onset or progressive headache, especially in middle age Previous headache history or lack thereof / Pregnancy / Papilledema / Progression
Dodick (2003) Adv Stud Med
![Page 8: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/8.jpg)
Medication Overuse and Medication Overuse HA
Use combination therapies sparingly and with caution as most contain caffeine (caffeine withdrawal headache)
Acute treatments can contribute to HA frequency:
• NSAIDs when taken more than 14 days per month
• Triptans when taken more than 10 days per month
• Opioids and opioid-like medications (e.g., tramadol) > 6 days per month
• Butalbital-containing compounds > 4 days per month
![Page 9: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/9.jpg)
EpidemiologyOne-year period prevalence
MIGRAINE 10-13%
CLUSTER HEADACHE 0.14%
TENSION-TYPE HEADACHE 38.3-74%
Rasmussen et al. 1991, Stewart et al. 1992, Schwartz et al. 1998, Lipton et al. 2001, Natoli et al. 2010
CHRONIC MIGRAINE 1.3-2.4 %
![Page 10: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/10.jpg)
Migraine
A chronic condition with episodic manifestations
Familial disorder with a genetic component
Monogenic forms are rare and include hemiplegic migraine and other complicated migraine disorders.
Environmental triggers
Episodic or chronic migraine based on attack frequency• Episodic < 15 days/month
• Chronic ≥ 15 days/month for at least 3 months
The most important categories are migraine with and without aura
![Page 11: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/11.jpg)
At least two of the following characteristics:
• Unilateral location
• Pulsating quality
• Moderate or severe intensity
• Aggravation by routine physical activities
Headache duration4-72 hours
At least one of the following:
• Nausea and/or vomiting
• Photophobia and phonophobia
Migraine without Aura
![Page 12: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/12.jpg)
Migraine with Aura
• Migraine with aura is seen in 20% of patients with migraine
• Attributed to the phenomenon of cortical spreading depression (Ward 2012)
• Fully reversible visual symptoms (flickering lights, spots or lines and/or loss of vision)
• Fully reversible sensory symptoms (pins and needles and/or numbness)
• Fully reversible dysphasic speech disturbance
• No motor weakness
![Page 13: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/13.jpg)
Migraine with AuraICHD-2 Diagnostic Criteria for Typical Aura
a. At least two attacks fulfilling criteria B-Eb. Fully reversible visual and/or sensory and/or speech symptoms but no motor
weakness
c. At least two of the followinga. Visual symptoms including positive features (i.e. flickering lights, spots and lines) and/or
negative features (i.e. loss of vision) and/or unilateral sensory symptoms including positive features (i.e. pins and needles) and/or negative features (i.e. numbness)
b. At least one symptom develops gradually over ≥ 5 min and/or different symptoms occur in succession
c. Each symptom lasts ≥ 5 min and ≤ 60 min
d. A headache that meets criteria for migraine without aura begins during the aura or follows aura within 60 min
e. Not attributed to another disorder
![Page 14: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/14.jpg)
Dura
Trigeminal nerves
TNC
PAIN
TGVS activated
Trigeminovascular System
Ashina 2011
CSD
![Page 15: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/15.jpg)
Migraine Pathophysiology: Trigeminovascular System
Goadsby et al. NEJM 2002
![Page 16: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/16.jpg)
Triptans are first-line treatment for moderate-to-severe attacks
Specific 5-HT1 (serotonin) agonists at the neurovascular junction
• Available subcutaneous (SC), PO, nasal spray (NS)
• Early treatment is key
Ergots (e.g. dihydroergotamine or DHE)
• Non-specific 5-HT1 agonist at the neurovascular junction
• Available IV, IM, SC, NS
• Do not use within 24 hours of a triptan
* Both are contraindicated in vascular disease, uncontrolled hypertension, hemiplegic/basilar migraine, and pregnancy
Migraine Treatment
![Page 17: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/17.jpg)
Triptans
Generic Brand Formulations Dosesa Maximum Daily Dose
Sumatriptan
Sumatriptan + Naproxen sodium
Imitrex
Treximet
Tablet
Nasal spray
Subcutaneous injection
Fixed-dose combination tablet
25 mg, 50 mg, 100 mg
5 mg, 20 mg
4 mg, 6 mg
85-mg sumatriptan +
500-mg naproxen sodium
200 mg
40 mg
12 mg
2 tablets
Zolmitriptan Zomig
Zomig-ZMT
Zomig
Tablet
Orally dissolving tablet
Nasal spray
2.5 mg, 5.0 mg
2.5 mg, 5.0 mg
5.0 mg
10 mg
10 mg
10 mg
Rizatriptan Maxalt
Maxalt-MLT
Tablet
Orally dissolving tablet
5 mg, 10 mg
5 mg, 10 mg
30 mgb
30 mgb
Naratriptan Amerge Tablet 1.0 mg, 2.5 mg 5 mg
Almotriptan Axert Tablet 6.25 mg, 12.5 mg 25 mg
Frovatriptan Frova Tablet 2.5 mg 7.5 mg
a Optimal dose, when known, is bolded.b15 mg if also on propranolol.
Adapted from Tepper SJ. Acute treatment of migraine. Continuum 2006;12:87-105.
![Page 18: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/18.jpg)
Coming Soon… CGRP Monoclonal Antibodies
The evidence for…
• A potent vasodilator released during migraine attacks
• Persistent elevation in CM
• CGRP infusion triggers migraine in migraine patients
• Triptans normalize CGRP levels
• CGRP antagonists (“gepants”) abort acute attacks
![Page 19: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/19.jpg)
CGRP mAbs in Development
Humanized antibodies
LY2951742/galcanezumab (SQ) t1/2 = 28h
ALD403/eptinezumab (IV) t1/2 = 31h
TEV-48215/fremanezumab
Fully human mAb
AMG-334/erenumab (SQ) t1/2 = 21h
*Proven efficacy, tolerability and few AEs in phase 2 randomized control trials.
![Page 20: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/20.jpg)
Treatment of Refractory Migraine
Oral abortive treatments
• Naproxen sodium 440-550 mg twice a day with food
• Metoclopromide (MTC) 10 mg to 20 mg, prochlorperazine (PCZ) 5 mg to 10 mg, OR promethazine 25 mg with Benadryl +/- NSAID morning and bedtime for 6 doses
• Dexamethasone 4 mg TID, BID, once (6 total tabs over 3 days)
• Naratriptan 2.5 mg twice a day for 5 days
![Page 21: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/21.jpg)
Indications for Prevention
Recurring attacks that interfere with patient’s daily routine despite appropriate acute treatment
> 3 attacks per month
Trouble with or limited acute therapies
Patient preference
Missed work, family, and/or social events due to headache
Frequent, prolonged, or bothersome aura
HM, basilar migraine, migrainous infarction
![Page 22: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/22.jpg)
Migraine Preventive Drugs
Start at a low dose and titrate slowly. May take up to 3 months at target dose for clinical effect
• Amitriptyline can be helpful at right dose after 7-10 days
• OnabotulinumtoxinA can begin to work at 3-4 weeks, but works better with subsequent treatments (over at least a 5-yr period)
• Nerve block and trigger point injections work quickly and can be done serially for prevention
![Page 23: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/23.jpg)
Migraine Preventive Treatments by Grade
Level A: (established efficacy)• Divalproex sodium (250 to 1500 mg daily)
Common side effects include weight gain, tremor, and hair loss
Monitor for potential liver and blood abnormalities Known teratogen
• Topiramate (25 to 150 mg daily) Paresthesias may occur early
Cognitive side effects are dose dependent
Known teratogen
• Metoprolol (50 to 150 mg)• Propranolol (as little as 10 mg)• Timolol (10 to 20 mg)• Behavioral therapy (biofeedback, learned controlled, and progressive muscle relaxation)
![Page 24: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/24.jpg)
Migraine Preventive Treatments by Grade
Level B: (probable efficacy)
• Amitriptyline (as little as 5 mg )
• Venlafaxine (37.5 mg to 225 mg)
• Atenolol (50-100 mg)
• Nadolol (20-160 mg)
• OnabotulinumtoxinA
• Mg, B2
• sTMS (acute treatment only), tSNS (Cefaly® device)
![Page 25: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/25.jpg)
Migraine Preventive Treatments by Grade
Level C: (possible efficacy)
• Lisinopril (10 mg BID)
• Candesartan (16 mg daily)
• Clonidine
• Tizanidine
• Guanfacine
![Page 26: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/26.jpg)
Migraine Preventive Treatments by Grade
Level U: (inadequate/conflicting data)
• Gabapentin
• Verapamil
• Fluoxetine
• sTMS for prevention
![Page 27: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/27.jpg)
Other Treatment Options…
Magnesium oxide - 400 mg twice a day
Riboflavin (vitamin B2) - 400 mg daily
Butterbur extract (Petadolex) - 50 mg three times a day
CoQ10
Feverfew
A comprehensive treatment plan should also include• Education and reassurance• Identifying and avoiding triggers to prevent attacks• Non-pharmacologic treatmentso Relaxation, Biofeedback, cognitive-behavioral therapyo Lifestyle regulation
• Physical and alternative medicine when appropriate• Periodic reassessment of the plan
![Page 28: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/28.jpg)
The most common of all primary headache disorders with lifetime prevalence estimated between 30 to 78%
Both migraine and TTH are long-duration headache disorders with episodic and chronic (≥ 15 days of headache/month) forms.
Pathophysiology is poorly understood (Schwartz et al 1998). Pericranial myofascialmechanisms are likely as is central sensitization in the chronic form.
Genetic and environmental factors may also play a role.
Tension-Type Headache
![Page 29: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/29.jpg)
Tension-Type Headache
ICHD-2 Diagnostic Criteria for TTH
Headache lasting from 30 min to 7 daysHA has ≥ 2 of the following characteristics• Bilateral location• Pressing/tightening (non-pulsating) quality• Mild or moderate intensity• Not aggravated by routine physical activity
Both of the following• No nausea or vomiting• No more than one of the following: photophobia and phonophobia
Not attributable to another disorder
![Page 30: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/30.jpg)
Treatment of TTHAcute treatment with simple analgesics is generally effective• Acetaminophen 500 – 1000 mg • Aspirin 500 – 1000 mg
NSAIDs are considered the acute-treatment drug of choice• Ibuprofen 200 – 800 mg no more than every 6 hours• Naproxen 375 – 550 mg no more than every 12 hours• Ketoprofen 25 – 50 mg no more than every 8 hours
Consider headache prevention in patients with chronic TTH (≥15 days/month):• Amitriptylineo A non-selective serotonin reuptake inhibitor
o 10 mg to 75 mg per day
• Mirtazapine and venlafaxine are other options for preventiono Mirtazapine up to 30 mg/day
o Venlafaxine up to 150 mg/day
![Page 31: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/31.jpg)
Goals of Preventive Treatment
Reduce frequency and severity of attacks
Improve function and reduce disability (ictal and inter-ictal)
Improve acute treatment response
Consider comorbid condition(s)
![Page 32: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/32.jpg)
• Known to contribute to headache frequency when take more than 6 days per month
Opioids are best avoided for headache as they can sensitize the CNS to pain
![Page 33: Headache A Practical Approach - IntermountainPhysician · 2017. 12. 1. · Headache –A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD ... Migraine](https://reader033.fdocuments.us/reader033/viewer/2022051901/5fefb054f1db7f4a473a94f1/html5/thumbnails/33.jpg)
ReferencesBenemei S, Ashina M, et al. Triptans and CGRP blockade - impact on the cranial vasculature. Headache Pain 2017 Oct 10;18(1):103.
Edvinsson L and Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 2017 Jan 1:333102417736900. doi: 10.1177/0333102417736900. [Epub ahead of print]
Eikermann-Haerter K and Moskowitz M. Pathophysiology of Aura. In Silberstein SD, Lipton RB, and Dodick DW, editors (2008). Wolff’s Headache and Other Head Pain: Oxford University Press, New York, pp. 431-447.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(suppl 1):9-160.
Kelley NE & Tepper DE. Rescue therapy for acute migraine, Part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache 2012;52:467-482.
Olesen J. Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs. Pain 1991;46:125-132.
Olesen J, Tfelt-Hansen P, Ramadan N, et al. The Headaches. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
Rasmussen BK, Jensen R, Schroll M, et al. Epidemiology of headache in a general population – a prevalence study. J Clin Epidemiol 1991;44:1147-57.
Siow HC, Young WB, Silberstein SD. Neuroleptics in headache. Headache 2005;45:358-371.
Ward TN. Migraine diagnosis and pathophysiology. In A.E. Miller (Ed.), Continuum lifelong learning neurol 2012;18(4):753-763.